Trial Profile
A prospective trial will investigate the efficacy and safety of epratuzumab as a thorium-227-labeled antibody in patients with advanced non-Hodgkin's lymphoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 02 Mar 2016
Price :
$35
*
At a glance
- Drugs Epratuzumab-Th-227 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2016 New trial record
- 26 Feb 2016 According to Immunomedics media release, Bayer started studying epratuzumab as a thorium-227-labeled antibody in patients with advanced non-Hodgkin lymphoma.